Table 5 Comparison between nanomedicine and non-nanomedicine against HMs
Drugs | Carrier | Outcomes compared with non-nanomedicine or free drugs | Ind. | References |
|---|---|---|---|---|
Ara-C, DNR | Liposome | Exhibited potent and direct ex vivo cytotoxicity against AML blasts | Leu | [39] |
VCR | Liposome | Improved the pharmacokinetics and pharmacodynamics of vincristine | Leu | [38] |
C6-ceramide | Liposome | Selective inhibition of the glycolytic pathway in CLL cells | CLL | [51] |
DOX | AlPcS | Enhanced the cellular uptake of AlPcS three times and PDT therapy | Leu | [250] |
Platinum | MSN | Exhibited unprecedented enhanced cytotoxicity to cancerous cells | Leu | [100] |
DAC,BTZ | PEG-PCL | Good stability, slow release profile, and superior anticancer effects | MM | [253] |
As4S4 | Realgar NPs | Significantly depleted the stem-like proportion and clonogenicity | MM | [254] |